Introduction {#s1}
============

Stroke is a common neurological disease and a leading cause of death and long-term disability worldwide [@pone.0046495-Bonita1]. Strong evidence from genetic association studies indicates that genetic predisposition, in addition to such recognized risk factors as hypertension, smoking, diabetes, obesity, and advanced age, contributes to the development of stroke [@pone.0046495-Sharma1]. Identification and characterization of genetic variations that play such a role may allow improved prognostication, therapy, and prevention.

The renin-angiotensin system (RAS) is a hormonal signaling mechanism implicated in the atherosclerosis and regulation of blood pressure [@pone.0046495-Jiang1]. Angiotensin-converting enzyme (ACE), a key enzyme in the RAS, plays important roles in vascular remodeling, atherosclerosis, and ischemic stroke [@pone.0046495-Morishita1]--[@pone.0046495-Raynolds1]. It catalyses the conversion of inactive angiotensin I to active angiotensin II, which is known to be involved in vascular hypertrophy, vasoconstriction, and atherosclerotic processes [@pone.0046495-Kim1]. The human *ACE* gene is located on chromosome 17q23, where an insertion/deletion polymorphism (I/D, dbSNP rs4646994) in intron 16 has been identified [@pone.0046495-Rigat1]. This polymorphism is based on the presence (insertion, I) or absence (deletion, D) of a 287-bp DNA fragment. The D allele of this polymorphism has been associated with elevated serum ACE level in a codominant pattern and has been investigated as a potential susceptibility factor for ischemic stroke. A large number of studies have reported the association between the I/D polymorphism of *ACE* gene and the risk of ischemic stroke, but the results were inconclusive [@pone.0046495-Sharma2]--[@pone.0046495-Kalita1]. The association between this polymorphism with ischemic stroke risk has attracted widespread attention in recent years and has been a research focus. However, each of these studies typically contained a few subjects and therefore was neither adequate nor sufficiently informative to clearly demonstrate an association. Moreover, these studies varied markedly by including different populations, sampling strategies, genotyping procedures, and quality control. Previously published meta-analyses reported significant associations between *ACE* I/D and risk of ischemic stroke [@pone.0046495-Sharma3]--[@pone.0046495-Xu1]. However, it remains unclear whether ethnicity, stroke subtype, subject source, and gender could affect the associations. Since then, additional many studies with a large sample size about this polymorphism on ischemic stroke risk have been reported. Subgroup analyses performed by ethnicity, stroke subtype, subject source, and gender were also possible now.

Therefore, we present herein the results of a large meta-analysis of published data investigating the association between *ACE* I/D and ischemic stroke for various genetic contrasts, in which we explored the between-studies heterogeneity and the existence of potential bias.

Materials and Methods {#s2}
=====================

Literature Search and Selection {#s2a}
-------------------------------

Two online electronic databases (PubMed and Embase) were searched for eligible articles through February 2012. The search was limited to English language full-text papers. Abstract, review or editorials were not included. The medical subject headings and terms used for the search were: stroke, brain infarction, and cerebrovascular disease in combination with ACE, angiotensin-converting enzyme, polymorphism, genotype, gene, or mutation. The references of all identified publications were searched for any additional studies, and the related articles option in PubMed was used to search for further potentially relevant articles.

Studies included in our meta-analysis have to meet the following criteria: (1) hypothesis-driven studies specific for *ACE* I/D polymorphism and provided cases of ischemic stroke (large-artery atherosclerosis, cardioembolic stroke, small-vessel stroke, or other determined and undetermined causes) and control subjects (population- or hospital-based controls), (2) had neuroimaging (CT or MRI) confirmation of an ischemic stroke diagnosis, (3) evaluation of *ACE* I/D polymorphism and ischemic stroke risk and (4) sufficient data for examining an odds ratio (OR) with 95% confidence interval (CI). Studies were excluded if: (1) patients were under 18 years of age, or (2) original genotype data was not reported. For duplicate publications, the smaller dataset was discarded.

Data Extraction {#s2b}
---------------

Two investigators (Z.Z. and G.X.) independently extracted data and reached a consensus on all of the items. For each study, the following characteristics were collected: the first author\'s last name, year of publication, country of origin, ethnicity, matching conditions, numbers of genotyped cases and controls, the genotype distribution of cases and controls for the *ACE* I/D polymorphism, source of control groups (population- or hospital-based controls), and genotyping methods. Different ethnic descents were categorized as European, Asian and African.

Statistical Analysis {#s2c}
--------------------

For each study, we first examined whether the genotype distribution in controls was consistent with Hardy-Weinberg equilibrium (HWE) by χ^2^ test. To measure the strength of genetic association for *ACE* I/D polymorphism, the ORs, together with the 95% CIs were calculated. The statistical significance of the summary OR was determined with the Z test, and *P*\<0.05 was considered as statistically significant. We first estimated the risks of the ID and DD genotypes on strokes, compared with the wild-type II homozygote, and then evaluated the risks of (ID/DD) vs II and DD vs (ID/II) on strokes, assuming dominant and recessive effects of the variant D allele, respectively. We also estimated the risks of D allele vs A allele. In addition, stratified analyses were performed by ethnicity, source of controls, subtype, gender, and HWE.

Heterogeneity among studies was assessed with the *Q*-test and *I* ^2^ statistics [@pone.0046495-Higgins1]. If there was no significant heterogeneity, the fixed-effects model (the Mantel-Haenszel method) was used to estimate the summary OR. Otherwise, the random-effects model (the DerSimonian and Laird method) was adopted. We conducted stratified analyses to explore possible explanations for heterogeneity and to test the robustness of the association.

Cumulative and recursive cumulative meta-analysis were performed to provide a framework for updating a genetic effect from all studies and to measure how much the genetic effect changes as evidence accumulates [@pone.0046495-Lau1], [@pone.0046495-Ioannidis1]. Therefore, cumulative meta-analysis demonstrates the trend in risk effect, and recursive cumulative meta-analysis indicates the stability in risk effect.

We also performed sensitivity analyses to evaluate the stability of the results. A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual data to the pooled ORs. For assessment of potential publication bias, we used funnel plots and Egger\'s linear regression test. Moreover, we performed the Duval and Tweedie nonparametric trim and fill procedure to further assess potential effects of publication bias [@pone.0046495-Duval1]. This method considers the possibility of hypothetical missing studies, and recalculates a pooled estimate. All analyses were done with STATA version 11.0 (StataCorp, College Station, TX).

Results {#s3}
=======

Literature Search {#s3a}
-----------------

A flow diagram of the literature search is shown in [Figure 1](#pone-0046495-g001){ref-type="fig"}. Total searches yielded 415 entries. Of these, 318 studies were excluded after reading the title or abstract because of obvious irrelevance to our study aim. Ninety-seven studies appeared to be potentially relevant for inclusion in our study. Twenty studies were excluded because of overlapping cases or their data were not extractable. Seventy-seven full-text articles were reviewed. Twenty-seven studies were further excluded for the following reasons: abstract, review or editorials (n = 22); no control population (n = 4); or children (n = 1). Therefore, a total of 50 studies met the inclusion criteria [@pone.0046495-Sharma2]--[@pone.0046495-Kalita1], [@pone.0046495-Ueda1]--[@pone.0046495-Markoula1].

![Flow diagram of the literature search.](pone.0046495.g001){#pone-0046495-g001}

Study Characteristics {#s3b}
---------------------

The characteristics of included studies are summarized in [Table 1](#pone-0046495-t001){ref-type="table"}. The 50 included studies were published between 1994 and 2011 and comprised a total of 10 070 cases and 22 103 controls. There were 26 studies of Asian descendents, 23 studies of European descendents, and 1 study of African descendents. Of the 50 studies, 42 studies used frequency-matched controls to the cases by the age or sex. A classic polymerase chain reaction assay was performed in all of the 50 studies; however, only 20 (40%) studies mentioned quality control on genotyping. The genotype distributions among the controls of all studies were in agreement with HWE except for eight studies.

10.1371/journal.pone.0046495.t001

###### Main characteristics of selected studies.

![](pone.0046495.t001){#pone-0046495-t001-1}

  First author                                               Year    Country    Ethnicity   Sample size   Matching criteria   Genotyping method   Quality control  
  --------------------------------------------------------- ------ ----------- ----------- ------------- ------------------- ------------------- ----------------- -----
  Sharma [@pone.0046495-Sharma2]                             1994      UK       European        100              73              Age and sex            PCR         No
  Ueda [@pone.0046495-Ueda1]                                 1995      UK       European        488              188             Age and sex            PCR         Yes
  Catto [@pone.0046495-Catto1]                               1996      UK       European        406              215             Age and sex            PCR         Yes
  Margaglione [@pone.0046495-Margaglione1]                   1996     Italy     European        101              109                 Sex                PCR         No
  Kario [@pone.0046495-Kario1]                               1996     Japan       Asian         138              104             Age and sex            PCR         Yes
  Agerholm-Larsen [@pone.0046495-AgerholmLarsen1]            1997    Denmark    European        452             9038                 Age                PCR         Yes
  Nakata [@pone.0046495-Nakata1]                             1997     Japan       Asian         55               61              Age and sex            PCR         No
  Doi [@pone.0046495-Doi1]                                   1997     Japan       Asian         181              271             Age and sex            PCR         Yes
  Seino [@pone.0046495-Seino1]                               1998     Japan       Asian         26               28              Age and sex            PCR         No
  Pfohl [@pone.0046495-Pfohl1]                               1998    Germany    European        91               297               **--**               PCR         Yes
  Shen [@pone.0046495-Shen1]                                 1998     China       Asian         44               62              Age and sex            PCR         No
  Xu [@pone.0046495-Xu2]                                     1998     China       Asian         65               117                 Age                PCR         No
  Kostulas [@pone.0046495-Kostulas1]                         1999    Sweden     European        96               93              Age and sex            PCR         No
  Notsu [@pone.0046495-Notsu1]                               1999     Japan       Asian         175              213                 Sex                PCR         Yes
  Zee [@pone.0046495-Zee1]                                   1999      USA      European        338              338                 Age                PCR         Yes
  Lin [@pone.0046495-Lin1]                                   2000     China       Asian         306              300             Age and sex            PCR         Yes
  Wei [@pone.0046495-Wei1]                                   2000     China       Asian         87               257                 Age                PCR         No
  Zhang [@pone.0046495-Zhang2]                               2001     China       Asian         165              106             Age and sex            PCR         No
  Zhang [@pone.0046495-Zhang1]                               2001     China       Asian         74               72                  Sex                PCR         No
  Ohkubo [@pone.0046495-Ohkubo1]                             2002     Japan       Asian         69               294             Age and sex            PCR         No
  Szolnoki [@pone.0046495-Szolnoki1]                         2003    Hungary    European        867              743             Age and sex            PCR         No
  UM [@pone.0046495-Um1]                                     2003     Korea       Asian         208              636             Age and sex            PCR         No
  Yuan [@pone.0046495-Yuan1]                                 2003     China       Asian         122             1229                 Age                PCR         No
  Zhang [@pone.0046495-Zhang3]                               2004     Japan       Asian         151              150             Age and sex            PCR         Yes
  Karagiannis [@pone.0046495-Karagiannis1]                   2004    Greece     European        100              100             Age and sex            PCR         Yes
  Wang [@pone.0046495-Wang1]                                 2004     China       Asian         46               43                **--**               PCR         No
  Rubattu [@pone.0046495-Rubattu1]                           2004     Italy     European        215              236                 Age                PCR         Yes
  Brenner [@pone.0046495-Brenner1]                           2005    France     European        459              459             Age and sex            PCR         Yes
  Pera [@pone.0046495-Pera1]                                 2006    Poland     European        368              556             Age and sex            PCR         No
  Dikmen [@pone.0046495-Dikmen1]                             2006    Turkey     European        141              50                **--**               PCR         No
  Gao [@pone.0046495-Gao1]                                   2006     China       Asian         100              100             Age and sex            PCR         Yes
  Tuncer [@pone.0046495-Tuncer1]                             2006    Turkey     European        108              79              Age and sex            PCR         No
  Tseng [@pone.0046495-Tseng1]                               2007     China       Asian         92               780               **--**               PCR         Yes
  Gormley [@pone.0046495-Gormley1]                           2007      UK       European        299              600             Age and sex            PCR         No
  Li [@pone.0046495-Li1]                                     2007     China       Asian         454              334                 Sex                PCR         No
  Lalouschek [@pone.0046495-Lalouschek1]                     2007    Austria    European        450              817               **--**               PCR         Yes
  Polupanov [@pone.0046495-Polupanov1]                       2007    Kirghiz      Asian         69               64                  Age                PCR         No
  Gawel [@pone.0046495-Gawel1]                               2007    Poland     European        66               45                  Age                PCR         No
  Hong [@pone.0046495-Hong1]                                 2008     Korea       Asian         232              225             Age and sex            PCR         No
  Munshi [@pone.0046495-Munshi1]                             2008     India       Asian         162              150             Age and sex            PCR         No
  Mollsten [@pone.0046495-Mollsten1]                         2008    Sweden     European        222              542             Age and sex            PCR         Yes
  Tascilar [@pone.0046495-Tascilar1]                         2009    Turkey     European        157              85                **--**               PCR         No
  Saidi [@pone.0046495-Saidi1]                               2009    Tunisia     African        228              323             Age and sex            PCR         No
  Celiker [@pone.0046495-Celiker1]                           2009    Turkey     European        162              107               **--**               PCR         No
  Li [@pone.0046495-Li2]                                     2010     China       Asian         76               311             Age and sex            PCR         Yes
  Domingues-Montanari [@pone.0046495-DominguesMontanari1]    2010     Spain     European        519              540               **--**               PCR         No
  Kalita [@pone.0046495-Kalita1]                             2011     India       Asian         193              188             Age and sex            PCR         Yes
  Chutinet [@pone.0046495-Chutinet1]                         2011   Thailand      Asian         141              167                 Age                PCR         No
  Markoula [@pone.0046495-Markoula1]                         2011    Greece     European        176              178             Age and sex            PCR         Yes
  Indrajaya [@pone.0046495-Indrajaya1]                       2011   Indonesia     Asian         30               30              Age and sex            PCR         No

Quantitative Synthesis {#s3c}
----------------------

Overall, the variant genotypes of *ACE* I/D polymorphism were associated with a significantly higher risk of ischemic stroke in different genetic models when all the eligible studies were pooled into the meta-analysis. As shown in [Table 2](#pone-0046495-t002){ref-type="table"}, the variant heterozygote ID and homozygote DD, were associated with a significantly higher risk of ischemic stroke in a dose-response manner, compared with the wild-type homozygote II (OR = 1.16, 95% CI: 1.06--1.26 for ID and 1.54, 1.34--1.78 for DD; *P* ~trend~\<0.001). In addition, significant main effects were also observed in dominant model, recessive model and allele contrast model (OR = 1.29, 95% CI: 1.17--1.43, OR = 1.37, 95% CI: 1.22--1.53 and OR = 1.27, 95% CI: 1.17--1.37, respectively).

10.1371/journal.pone.0046495.t002

###### Stratification analyses of the *ACE* I/D polymorphism on stroke risk.

![](pone.0046495.t002){#pone-0046495-t002-2}

  Variables            n        ID vs II        DD vs II   DD/ID vs II (dominant)   DD vs ID/II (recessive)     D vs I allele                                                                
  ------------------- ---- ------------------- ---------- ------------------------ ------------------------- ------------------- --------- ------------------- --------- ------------------- ---------
  Total                50   1.16 (1.06--1.26)    0.017       1.54 (1.34--1.78)              \<0.001           1.29 (1.17--1.43)   \<0.001   1.37 (1.22--1.53)   \<0.001   1.27 (1.17--1.37)   \<0.001
  Ethnicities                                                                                                                                                                                
  Asian                26   1.30 (1.12--1.50)    0.010       2.20 (1.70--2.84)              \<0.001           1.54 (1.30--1.82)   \<0.001   1.87 (1.51--2.31)   \<0.001   1.52 (1.33--1.75)    0.185
  European             23   1.03 (0.94--1.12)    0.555       1.12 (1.01--1.23)               0.627            1.06 (0.98--1.15)    0.502    1.10 (1.02--1.18)    0.684    1.06 (1.01--1.12)    0.465
  Source of control                                                                                                                                                                          
  HB                   28   1.14 (1.04--1.25)    0.200       1.75 (1.41--2.16)              \<0.001           1.33 (1.16--1.54)   \<0.001   1.53 (1.30--1.79)   \<0.001   1.34 (1.20--1.50)   \<0.001
  PB                   22   1.17 (1.01--1.35)    0.009       1.34 (1.11--1.62)              \<0.001           1.24 (1.08--1.44)    0.001    1.21 (1.04--1.41)   \<0.001   1.19 (1.07--1.32)   \<0.001
  HWE                                                                                                                                                                                        
  Yes                  42   1.16 (1.06--1.28)    0.014       1.55 (1.32--1.80)              \<0.001           1.29 (1.16--1.43)   \<0.001   1.37 (1.22--1.54)   \<0.001   1.26 (1.16--1.36)   \<0.001
  No                   8    1.13 (0.91--1.40)    0.246       1.57 (0.99--2.48)               0.005            1.34 (0.95--1.90)    0.011    1.42 (0.97--2.10)    0.003    1.36 (1.02--1.84)   \<0.001
  Subtype                                                                                                                                                                                    
  SVD                  17   1.16 (1.00--1.33)    0.128       1.45 (1.13--1.87)               0.011            1.25 (1.04--1.50)    0.045    1.30 (1.06--1.59)    0.006    1.20 (1.05--1.36)    0.003
  LVD                  17   1.09 (0.94--1.26)    0.141       1.47 (1.07--2.04)              \<0.001           1.24 (0.99--1.53)    0.014    1.36 (1.04--1.76)   \<0.001   1.23 (1.04--1.46)   \<0.001
  Gender                                                                                                                                                                                     
  Male                 5    1.16 (0.76--1.79)    0.035       1.11 (0.83--1.49)               0.078            1.20 (0.78--1.85)    0.018    1.04 (0.82--1.32)    0.476    1.13 (0.87--1.45)    0.041
  Female               5    1.26 (0.92--1.73)    0.090       2.16 (0.86--5.41)               0.003            1.61 (0.87--2.99)    0.014    1.46 (0.87--2.46)    0.050    1.37 (0.93--2.02)    0.008

*P* value of Q-test for heterogeneity test.

HB: Hospital-based; PB: Population-based; SVD: small vessel disease; LVD: large vessel disease.

In the stratified analysis by ethnicity, significantly higher risks were found in Asians (ID vs II: OR = 1.30, 95% CI = 1.12--1.50; DD vs II: OR = 2.20, 95% CI = 1.70--2.84; dominant model: OR = 1.54, 95% CI = 1.30--1.82; recessive model: OR = 1.87, 95% CI = 1.51--2.31; allele model: OR = 1.52, 95% CI = 1.33--1.75) but with borderline statistical significance in Europeans (DD vs II: OR = 1.12, 95% CI = 1.01--1.23; recessive model: OR = 1.10, 95% CI = 1.02--1.18; allele model: OR = 1.06, 95% CI = 1.01--1.12; [Fig. 2](#pone-0046495-g002){ref-type="fig"}). Moreover, when stratified by source of control, statistically significantly elevated risk was also observed, and this elevated risk was more pronounced among hospital-based studies ([Table 2](#pone-0046495-t002){ref-type="table"}).

![Forest plot of stroke risk associated with the *ACE* I/D polymorphism (DD vs ID/II).](pone.0046495.g002){#pone-0046495-g002}

In the present meta-analysis, seventeen studies provided detailed genotype information according to stroke subtype. As shown in [Table 2](#pone-0046495-t002){ref-type="table"}, significantly higher stroke risk was found in small vessel disease (SVD) but with borderline statistical significance in large vessel disease (LVD). However, in the subgroup analysis by gender, we did not find significant associations in any genetic models.

The cumulative meta-analysis for the recessive model showed a trend of association as published data information accumulated ([Fig. 3](#pone-0046495-g003){ref-type="fig"}). In recursive cumulative meta-analysis, the relative change in the random effects ORs fluctuated around 1.00 until 2008 and then stabilized, indicating that there is sufficient evidence for investigating the association ([Fig. 4](#pone-0046495-g004){ref-type="fig"}).

![Results of the cumulative meta-analysis.\
The random effects pooled OR with 95% CI at the end of each information step is shown.](pone.0046495.g003){#pone-0046495-g003}

![Results of the recursive cumulative meta-analysis.\
The relative change in random effects pooled OR in each information step (OR in the next year/OR in the current year) for the recessive model is shown.](pone.0046495.g004){#pone-0046495-g004}

Test of Heterogeneity {#s3d}
---------------------

Obvious heterogeneity between studies was observed in overall and subgroup analyses (*P*\<0.05, *I* ^2^\>30%, [Table 2](#pone-0046495-t002){ref-type="table"}). Then, we assessed the source of heterogeneity for recessive model comparison by ethnicity, sample size (subjects \>800), and source of controls. As a result, ethnicity (χ^2^ = 33.13, df = 2, *P*\<0.001) and source of controls (χ^2^ = 13.99, df = 1, *P*\<0.001), but not the sample size (χ^2^ = 3.13, df = 1, *P* = 0.077), was found to contribute to substantial heterogeneity.

Sensitivity Analyses {#s3e}
--------------------

Sensitivity analyses indicated that four independent studies [@pone.0046495-Notsu1], [@pone.0046495-Kalita1], [@pone.0046495-Zhang2], [@pone.0046495-Wang1] were the main origin of the heterogeneity in Asians. The heterogeneity was effectively lowered or removed after exclusion of these four studies (DD vs ID/II: *P* ~heterogeneity~ = 0.081). Although the genotype distributions in eight of the included studies did not follow HWE, the corresponding pooled ORs were not materially altered with or without including these studies ([Table 2](#pone-0046495-t002){ref-type="table"}). In further sensitivity analysis in which 1 study at a time was removed and the rest analyzed, the pooled ORs ranged from 1.32 to 1.39, indicating that the pooled estimate was robust and not influenced by a single study.

Publication Bias {#s3f}
----------------

Visual inspection of the Begg\'s funnel plot showed some asymmetry. Then, the Egger\'s test was used to provide statistical evidence of funnel plot asymmetry. As expected, the results indicated an obvious evidence of publication bias (t = 3.70, *P* = 0.001 for DD vs ID/II). Random-effects OR corrected for publication bias using the trim and fill method was 1.19 (95% CI, 1.05--1.35) for all studies combined. Correction for potential publication bias therefore did not materially alter the combined risk estimate.

Discussion {#s4}
==========

The present meta-analysis, including 10 070 cases and 22 103 controls from 50 published studies, explored the association between the *ACE* I/D polymorphism and stroke risk. We found that the variant genotypes of this polymorphism were associated with significant increase in overall stroke risk.

ACE activates angiotensin I and inactivates bradykinin, resulting in decreased tissue perfusion, vascular smooth muscle cell growth [@pone.0046495-Daemen1], and stimulation of plasminogen-activator inhibitor type I [@pone.0046495-Ridker1]. Moreover, plasma ACE concentration is an important factor in cardiovascular and cerebrovascular risk profiling, since chronic exposure to high levels of plasma ACE may result in vascular wall thickness and stiffness [@pone.0046495-Juo1]. Thus, the *ACE* gene is a good candidate gene for ischemic stroke. Early studies demonstrated a strong correlation between the D allele and levels of circulating, intracellular, and tissue activity of ACE [@pone.0046495-Rigat1], [@pone.0046495-Danser1]. Since both alleles have codominant effects on ACE levels, individuals who are homozygous for the D allele have the highest levels of the enzyme, those homozygous for the I allele have the lowest, and heterozygous individuals have an intermediate level. Given the important roles of ACE in the pathogenesis of cerebrovascular disease, it is biologically plausible that *ACE* polymorphism may modulate the risk of ischemic stroke. In present meta-analysis, we found that variant genotypes of *ACE* I/D polymorphism were associated with higher stroke risk, which was consistent with experimental findings.

Significant associations were found in Asians but with borderline statistical significance in Europeans, suggesting a possible role of ethnic differences in genetic backgrounds and the environment they lived in. The impact of this polymorphism may be masked by the presence of other as-yet unidentified causal genes involved in stroke development in Europeans. Other factors such as selection bias, different matching criteria may also play a role. The above differences may lead to the inconsistent results. In addition, there is only one reported study using African population for this polymorphism. So it is also likely that the observed ethnic differences may be due to chance because studies with small sample size may have low statistical power to detect a slight effect. Thus, additional studies are warranted to further validate ethnic difference in the effect of this polymorphism on stroke risk, especially in Africans.

In the subgroup analysis by subtype, significantly higher stroke risk was observed in SVD but with borderline statistical significance in LVD. Stroke is a heterogenous disease and it is possible that *ACE* I/D polymorphism may play different roles in the differing subtypes of strokes. Our findings indicate that genetic risk factors for different subtypes are likely different, supporting the view that they are pathologically distinct entities, with SVD having a greater genetic liability compared to LVD.

No significant association between variant genotypes and stroke risk was observed when the included studies were stratified by gender. The null result may be due to limited number of studies with available data, which had insufficient statistical power to detect a slight effect or may have generated a fluctuated risk estimate.

Our findings confirmed results from previous meta-analyses. With the accumulative evidence, we were able to enhance the precision of the risk estimates and perform subgroup analyses to explore sources of heterogeneity, thereby increasing the clinical relevance of our findings. However, some limitations of this meta-analysis should be addressed. First, lacking of the original data of the reviewed studies limited our further evaluation of potential interactions, because the gene-gene interaction and gene-environment interaction may modulate stroke risk. Second, a potential publication bias may exist, as shown by the funnel plot and the Egger\'s test. Nevertheless, correction for this bias using the trim and fill method did not materially alter the combined risk estimate.

In conclusion, this meta-analysis provided evidence of the association between the *ACE* I/D polymorphism and stroke risk, supporting the hypothesis that the *ACE* I/D polymorphism may be a low-penetrance susceptibility marker of stroke. However, additional large studies are warranted to validate our findings. Future studies should use standardized genotyping methods and homogeneous patients and well-matched controls and include multi-ethnic populations. Furthermore, detailed gene-gene interaction and gene-environment interaction should also be considered in future studies, which should lead to better understanding of the association between the *ACE* I/D polymorphism and stroke risk.
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